Heart and lung transplantation in children

Lancet

Volumn 368, Issue 9529, 2006, Pages 53-69

  Webber, Steven A ^a,b   McCurry, Kenneth ^a,b   Zeevi, Adriana ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALEMTUZUMAB; ANTHRACYCLINE DERIVATIVE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CALCIUM ANTAGONIST; CORTICOSTEROID; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; GANCICLOVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; OKT 3; POLYCLONAL ANTIBODY; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ASSISTED CIRCULATION; BONE DENSITY; BONE DISEASE; BONE MARROW SUPPRESSION; CARDIAC GRAFT REJECTION; CHILDHOOD CANCER; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DISEASE EXACERBATION; DISEASE MODEL; GINGIVA HYPERPLASIA; HEART TRANSPLANTATION; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; LUNG GRAFT REJECTION; LUNG TOXICITY; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; MOUTH ULCER; NEPHROTOXICITY; NONHUMAN; OPPORTUNISTIC INFECTION; PALLIATIVE THERAPY; PEDIATRIC SURGERY; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURGICAL TECHNIQUE; SURVIVAL; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; WOUND HEALING IMPAIRMENT;

EID: 33745364003     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68969-1     Document Type: Review

References (148)

1. Webber S., and Neches W. Historical notes. Section 5, cardiac transplantation. In: Tejani A., Harmon W., and Fine R. (Eds). Pediatric solid organ transplantation (2000), Munksgaard, Munksgaard, Copenhagen 313-318
2. Kantrowitz A., Haller J., Joos H., Cerruti M., and Carstensen H. Transplantation of the heart in an infant and an adult. Am J Cardiol 22 (1968) 782-790
3. Mendeloff E. The history of pediatric heart and lung transplantation. Pediatr Transplant 6 (2002) 270-279
4. Boucek M., Edwards L., Keck B., Trulock E., Taylor D., and Hertz M. Registry of the International Society for Heart and Lung Transplantation: eighth official pediatric report-2005. J Heart Lung Transplant 24 (2005) 968-982
5. Liou T., Adler F., and Huang D. Use of lung transplantation survival models to refine patient selection in cystic fibrosis. Am J Respir Crit Care Med 171 (2005) 1053-1059
6. Webber S. The current state of, and future prospects for, cardiac transplantation in children. Cardiol Young 13 (2003) 64-83
7. Russo L., and Webber S. Pediatric heart transplantation: immunosuppression and its complications. Curr Opin Cardiol 19 (2004) 104-109
8. Boucek R., and Boucek M. Pediatric heart transplantation. Curr Opin Pediatr 14 (2002) 611-619
9. Mallory G., and Spray T. Paediatric lung transplantation. Eur Respir J 24 (2004) 839-845
10. Shah M., Schroeder T., and First M. Guidelines for immunosuppression management and monitoring after transplantation in children. Transplant Rev (Orlando) 13 (1999) 83-97
11. West L. Developmental aspects of immunomodulation: exploiting the immature immune system for organ transplantation. Transpl Immunol 9 (2002) 149-153
12. Fricker F., Addonizio L., Bernstein D., et al. Heart transplantation in children: indications. Pediatr Transplant 3 (1999) 333-342
13. Fortuna R., Chinnock R., and Bailey L. Heart transplantation among 233 infants during the first six months of life: the Loma Linda experience. Clin Transpl (1999) 263-272
14. Tweddell J., Hoffman G., Mussatto K., et al. Improved survival of patients undergoing palliation of hypoplastic left heart syndrome: lessons learned from 115 consecutive patients. Circulation 106 suppl 1 (2002) I82-I89
15. Ashburn D., McCrindle B., Tchervenkov C., et al. Outcomes after the Norwood operation in neonates with critical aortic stenosis or aortic valve atresia. J Thorac Cardiovasc Surg 125 (2003) 1070-1082
16. Chrisant M., Naftel D., Drummond-Webb J., et al. Fate of infants with hypoplastic left heart syndrome listed for cardiac transplantation: a multicenter study. J Heart Lung Transplant 24 (2005) 576-582
17. Ward K., Binns H., Chin C., Webber S., Canter C., and Pahl E. Pediatric heart transplantation for anthracycline cardiomyopathy: cancer recurrence is rare. J Heart Lung Transplant 23 (2004) 1040-1045
18. Dobbels F., Van Damme-Lombaert R., Vanhaecke J., and De Geest S. Growing pains: non-adherence with the immunosuppressive regimen in adolescent transplant recipients. Pediatr Transplant 9 (2005) 381-390
19. Blume E., Naftel D., Bastardi H., et al. Outcome of children bridged to heart transplant with ventricular assist devices: a multi-institutional study. Circulation 113 (2006) 2313-2319
20. Lower R., and Shumway N. Studies on orthotopic homotransplantation of the canine heart. Surg Forum 11 (1960) 18-25
21. El Gamel A., Yonan N., Grant S., et al. Orthotopic cardiac transplantation: Comparison of standard and bicaval Wythenshawe techniques. J Thorac Cardiovasc Surg 109 (1995) 721-730
22. Webber S., Fricker F., Michael M., et al. Orthotopic heart transplantation in children with congenital heart disease. Ann Thorac Surg 58 (1994) 1664-1669
23. Hsu D., Quaegebeur J., Michler R., et al. Heart transplantation in children with congenital heart disease. J Am Coll Cardiol 26 (1995) 743-749
24. Lamour J., Hsu D., Quaegebeur J., et al. Heart transplantation to a physiologic single lung in patients with congenital heart disease. J Heart Lung Transplant 23 (2004) 948-953
25. Huang J., Trinkaus K., Huddleston C., Mendeloff E., Spray T., and Canter C. Risk factors for primary graft failure after pediatric cardiac transplantation: importance of recipient and donor characteristics. J Heart Lung Transplant 23 (2004) 716-722
26. Mahle W., Vincent R., and Kanter K. Cardiac retransplantation in childhood: analysis of data from the United Network for Organ Sharing. J Thorac Cardiovasc Surg 130 (2005) 542-546
27. Fenton K., Webber S., Danford D., Gandhi S., Periera J., and Pigula F. Long-term survival after pediatric cardiac transplantation and postoperative ECMO support. Ann Thorac Surg 76 (2003) 843-846
28. Shaddy R. Pulmonary hypertension in pediatric heart transplantation. Prog Pediatr Cardiol 11 (2000) 131-136
29. Balzer D., Kort H., Day R., et al. Inhaled nitric oxide as a preoperative test (INOP test 1). Circulation 106 (2002) 76-81
30. Gajarski R., Mosca R., Ohye R., et al. Use of extracorporeal life support as a bridge to pediatric cardiac transplantation. J Heart Lung Transplant 22 (2003) 28-34
31. Fiser W., Yetman A., Gunselman R., et al. Pediatric arteriovenous extracorporeal membrane oxygenation (ECMO) as a bridge to cardiac transplantation. J Heart Lung Transplant 22 (2003) 770-777
32. Goldman A., Cassidy J., de Leval M., et al. The waiting game: bridging to paediatric heart transplantation. Lancet 362 (2003) 1967-1970
33. Helman D., Addonizio L., Morales D., et al. Implantable left ventricular assist devices can successfully bridge adolescent patients to transplant. J Heart Lung Transplant 19 (2000) 121-126
34. Reinhartz O., Keith F., El-Banayosy A., et al. Multi-center experience with the Thoratec ventricular assist device in children and adolescents. J Heart Lung Transplant 20 (2001) 439-448
35. Sharma M., Webber S., Gandhi S., et al. Pulsatile paracorporeal assist devices in children and adolescents with biventricular failure. ASAIO J 51 (2005) 490-494
36. Stiller B., Hetzer R., Weng Y., et al. Heart transplantation in children after mechanical circulatory support with pulsatile pneumatic assist device. J Heart Lung Transplant 22 (2003) 1201-1208
37. Kaczmarek I., Sachweh J., Groetzner J., et al. Mechanical circulatory support in pediatric patients with the MEDOS assist device. ASAIO J 51 (2005) 498-500
38. Minami K., Knyphausen E., Suzuki R., et al. Mechanical ventricular circulatory support in children; Bad Oeynhausen experience. Ann Thorac Cardiovasc Surg 11 (2005) 307-312
39. Reddy S., Laughlin K., and Webber S. Immunosuppression in pediatric heart transplantation: 2003 and beyond. Curr Treat Options Cardiovasc Med 5 (2003) 417-428
40. Baldwin J., Borovetz H., Duncan B., et al. The National Heart, Lung, and Blood Institute Pediatric Circulatory Support Program. Circulation 113 (2006) 147-155
41. Smith J., Nemeth T., and McDonald R. Current immunosuppressive agents: efficacy, side effects, and utilization. Pediatr Clin North Am 50 (2003) 1283-1300
42. Boucek Jr. R., Naftel D., Boucek M., et al. Induction immunotherapy in pediatric heart transplant recipients: a multicenter study. J Heart Lung Transplant 18 (1999) 460-469
43. Hershberger R., Starling R., Eisen H., et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 352 (2005) 2705-2713
44. Kobashigawa J., David K., Morris J., et al. Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids. Transplant Proc 37 (2005) 1333-1339
45. Chin C., Pittson S., Luikart H., et al. Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab. Transplantation 80 (2005) 477-481
46. Ford K., Cale C., Rees P., Elliott M., and Burch M. Initial data on basiliximab in critically ill children undergoing heart transplantation. J Heart Lung Transplant 24 (2005) 1284-1288
47. Pollock-Barziv S., Dipchand A., McCrindle B., Nalli N., and West L. Randomized clinical trial of tacrolimus- vs cyclosporine-based immunosuppression in pediatric heart transplantation: preliminary results at 15-month follow-up. J Heart Lung Transplant 24 (2005) 190-194
48. Webber S. Fifteen years of pediatric heart transplantation at the University of Pittsburgh: Lessons learned and future prospects. Pediatr Transplant 1 (1997) 8-21
49. Law Y., Yim R., Agatisa P., et al. Lipid profiles in pediatric thoracic transplant recipients are determined by their immunosuppressive regimens. J Heart Lung Transplant 25 (2006) 276-282
50. Kobashigawa J., Miller L., Russell S., et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 6 (2006) 1377-1386
51. Eisen H., Kobashigawa J., Keogh A., et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 24 (2005) 517-525
52. Keogh A., Richardson M., Ruygrok P., et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 110 (2004) 2694-2700
53. Eisen H., Tuzcu E., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349 (2003) 847-858
54. Lobach N., Pollock-Barziv S., West L., and Dipchand A. Sirolimus immunosuppression in pediatric heart transplant recipients: a single-center experience. J Heart Lung Transplant 24 (2005) 184-189
55. Sindhi R., Webber S., Venkataramanan R., et al. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation 72 (2001) 851-855
56. Garrean S., Massad M., Tshibaka M., Hanhan Z., Caines A., and Benedetti E. Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients. Clin Transplant 19 (2005) 698-703
57. Bestard O., Cruzado J., and Grinyo J. Calcineurin-inhibitor-sparing immunosuppressive protocols. Transplant Proc 37 (2005) 3729-3732
58. Meiser B., Reichart B., Adamidis I., Uberfuhr P., and Kaczmarek I. First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation. Am J Transplant 5 (2005) 827-831
59. Smith R., Wray J., Khaghani A., and Yacoub M. Ten year survival after paediatric heart transplantation: a single centre experience. Eur J Cardiothorac Surg 27 (2005) 790-794
60. Leonard H., Hornung T., Parry G., and Dark J. Pediatric cardiac transplant: results using a steroid-free maintenance regimen. Pediatr Transplant 7 (2003) 59-63
61. Billingham M., Cary N., Hammond M., et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. J Heart Transplant 9 (1990) 587-593
62. Stewart S., Winters G., Fishbein M., et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 24 (2005) 1710-1720
63. Reed E., Demetris A., Hammond E., et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 25 (2006) 153-159
64. Lietz K., John R., Burke E., et al. Immunoglobulin M-to-immunoglobulin G anti-human leukocyte antigen class II antibody switching in cardiac transplant recipients is associated with an increased risk of cellular rejection and coronary artery disease. Circulation 112 (2005) 2468-2476
65. Di F., Girnita A., Webber S., et al. Impact of ELISA-detected antibodies on pediatric cardiac allograft outcome. Hum Immunol 66 (2005) 513-518
66. Jacobs J., Quintessenza J., Boucek R., et al. Pediatric cardiac transplantation in children with high panel reactive antibody. Ann Thorac Surg 78 (2004) 1703-1709
67. Shaddy R., and Fuller T. The sensitized pediatric heart transplant candidate: causes, consequences, and treatment options. Pediatr Transplant 9 (2005) 208-214
68. Webber S., Naftel D., Parker J., et al. Late rejection episodes greater than 1 year after pediatric heart transplantation: risk factors and outcomes. J Heart Lung Transplant 22 (2003) 869-875
69. Chin C., Naftel D., Singh T., et al. Risk factors for recurrent rejection in pediatric heart transplantation: a multi-center experience. J Heart Lung Transplant 23 (2004) 178-185
70. Pahl E., Naftel D., Canter C., et al. Death after rejection with severe hemodynamic compromise in pediatric heart transplant recipients: a multi-institutional study. J Heart Lung Transplant 20 (2001) 279-287
71. Ibrahim J., Sweet S., Flippin M., et al. Rejection is reduced in thoracic organ recipients when transplanted in the first year of life. J Heart Lung Transplant 21 (2002) 311-318
72. Awad M., Webber S., Boyle G., et al. The effect of cytokine gene polymorphism on pediatric heart allograft outcome. J Heart Lung Transplant 20 (2001) 625-630
73. Zheng H., Webber S., Zeevi A., et al. MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol 63 (2002) 765-770
74. Zheng H., Webber S., Zeevi A., et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 3 (2003) 477-483
75. Ozawa S., Soyama A., Saeki M., et al. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet 19 (2004) 83-95
76. Boucek Jr. R., Boucek M., and Asante-Korang A. Advances in methods for surveillance of rejection. Cardiol Young 14 suppl 1 (2004) 93-96
77. Hsu D. Can non-invasive methodology predict rejection and either dictate or obviate the need for an endomyocardial biopsy in pediatric heart transplant recipients?. Pediatr Transplant 9 (2005) 697-699
78. McOmber D., Ibrahim J., Lublin D., et al. Non-ischemic left ventricular dysfunction after pediatric cardiac transplantation: treatment with plasmapheresis and OKT3. J Heart Lung Transplant 23 (2004) 552-557
79. Pophal S., Sigfusson G., Booth K., et al. Complications of endomyocardial biopsy in children. J Am Coll Cardiol 34 (1999) 2105-2110
80. Leonard Jr. G., Fricker F., Pruett D., Harker K., Williams B., and Schowengerdt Jr. K. Increased myocardial performance index correlates with biopsy-proven rejection in pediatric heart transplant recipients. J Heart Lung Transplant 25 (2006) 61-66
81. Rosenthal D., Chin C., Nishimura K., et al. Identifying cardiac transplant rejection in children: diagnostic utility of echocardiography, right heart catheterization and endomyocardial biopsy data. J Heart Lung Transplant 23 (2004) 323-329
82. Deng M., Eisen H., Mehra M., et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 6 (2006) 150-160
83. Seipelt I., Pahl E., Seipelt R., et al. Neointimal inflammation and adventitial angiogenesis correlate with severity of cardiac allograft vasculopathy in pediatric recipients. J Heart Lung Transplant 24 (2005) 1039-1045
84. Hathout E., Beeson W., Kuhn M., et al. Cardiac allograft vasculopathy in pediatric heart transplant recipients. Transpl Int 19 (2006) 184-189
85. Shirali G., Ni J., Chinnock R., et al. Association of viral genome with graft loss in children after cardiac transplantation. N Engl J Med 344 (2001) 1498-1503
86. Pahl E., Naftel D., Kuhn M., et al. The impact and outcome of transplant coronary artery disease in a pediatric population: a 9-year multi-institutional study. J Heart Lung Transplant 24 (2005) 645-651
87. Price J., Towbin J., Dreyer W., et al. Symptom complex is associated with transplant coronary artery disease and sudden death/resuscitated sudden death in pediatric heart transplant recipients. J Heart Lung Transplant 24 (2005) 1798-1803
88. Costello J., Wax D., Binns H., Backer C., Mavroudis C., and Pahl E. A comparison of intravascular ultrasound with coronary angiography for evaluation of transplant coronary disease in pediatric heart transplant recipients. J Heart Lung Transplant 22 (2003) 44-49
89. Kuhn M., Jutzy K., Deming D., et al. The medium-term findings in coronary arteries by intravascular ultrasound in infants and children after heart transplantation. J Am Coll Cardiol 36 (2000) 250-254
90. Kobashigawa J., Tobis J., Starling R., et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol 45 (2005) 1532-1537
91. Tham E., Yeung A., Cheng C., Bernstein D., Chin C., and Feinstein J. Experience of percutaneous coronary intervention in the management of pediatric cardiac allograft vasculopathy. J Heart Lung Transplant 24 (2005) 769-773
92. Mancini D., Pinney S., Burkhoff D., et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 108 (2003) 48-53
93. Kobashigawa J., Moriguchi J., Laks H., et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 24 (2005) 1736-1740
94. Mahle W., Vincent R., Berg A., and Kanter K. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation. J Heart Lung Transplant 24 (2005) 63-66
95. Keough W., and Michaels M. Infectious complications in pediatric solid organ transplantation. Pediatr Clin North Am 50 (2003) 1451-1469
96. Valantine H. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Heart Lung Transplant 23 suppl 1 (2004) S187-S193
97. Allen U., Farkas G., Hebert D., et al. Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: a case-control study. Pediatr Transplant 9 (2005) 450-455
98. Green M., and Webber S. Posttransplantation lymphoproliferative disorders. Pediatr Clin North Am 50 (2003) 1471-1491
99. Nalesnik M. The diverse pathology of post-transplant lymphoproliferative disorders: the importance of a standardized approach. Transpl Infect Dis 3 (2001) 88-96
100. Green M., Reyes J., Webber S., Michaels M., and Rowe D. The role of viral load in the diagnosis, management and possible prevention of Epstein-Barr virus-associated posttransplant lymphoproliferative disease following solid organ transplantation. Curr Opin Organ Transplant 4 (1999) 292-296
101. Green M., and Webber S. EBV viral load monitoring: unanswered questions. Am J Transplant 2 (2002) 894-895
102. Webber S., Naftel D., Fricker F., et al. Lymphoproliferative disorders after pediatric heart transplantation: a multi-institutional study. Lancet 367 (2006) 233-239
103. Milpied N., Vasseur B., Parquet N., et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in posttransplant B-lymphoproliferative disorders: a retrospective analysis on 32 patients. Ann Oncol 11 suppl 1 (2000) 113-116
104. Webber S., Harmon W., Faro A., et al. Anti-CD20 monoclonal antibody (Rituximab) for refractory PTLD after pediatric solid organ transplantation: multicenter experience from a registry and from a prospective clinical trial. Blood 104-1 (2004) 213a
105. Khanna R., Bell S., Sherritt M., et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA 96 (1999) 10391-10396
106. English R., Pophal S., Bacanu S., et al. Long-term comparison of tacrolimus and cyclosporine induced nephrotoxicity in pediatric heart transplant recipients. Am J Transplant 2 (2002) 769-773
107. Boyer O., Le Bidois J., Dechaux M., Gubler M., and Niaudet P. Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil. Transplantation 79 (2005) 1405-1410
108. Harmon W., McDonald R., Reyes J., et al. Pediatric transplantation, 1994-2003. Am J Transplant 5 (2005) 887-903
109. West L., Karamlou T., Dipchand A., Pollock-BarZiv S., Coles J., and McCrindle B. Impact on outcomes after listing and transplantation, of a strategy to accept ABO blood group-incompatible donor hearts for neonates and infants. J Thorac Cardiovasc Surg 131 (2006) 455-461
110. West L., Pollock-Barziv S., Dipchand A., et al. ABO incompatible heart transplantation in infants. N Engl J Med 344 (2001) 793-800
111. Fan X., Ang A., Pollock-Barziv S., et al. Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. Nat Med 10 (2004) 1227-1233
112. Rhee E., Canter C., Basile S., Naftel D., and Pediatric Heart Transplant Study. Sudden cardiac death prior to pediatric heart transplantation: would implantable defibrillators improve outcome?. J Heart Lung Transplant 24 suppl 1 (2005) 63
113. Mahle W., Kanter K., and Vincnet R. Disparities in outcome for black patients after pediatric heart transplantation. J Pediatr 147 (2005) 739-743
114. Nixon P., Fricker F., Noyes B., Webber S., Orenstein D., and Armitage J. Exercise testing in pediatric heart and/or lung transplant recipients. Chest 107 (1995) 1328-1335
115. Abarbanell G., Mulla N., Chinnock R., and Larsen R. Exercise assessment in infants after cardiac transplantation. J Heart Lung Transplant 23 (2004) 1334-1338
116. Wray J., and Radley-Smith R. Beyond the first year after pediatric heart or heart-lung transplantation: changes in cognitive function and behaviour. Pediatr Transplant 9 (2005) 170-177
117. Freier M., Babikian T., Pivonka J., et al. A longitudinal perspective on neurodevelopmental outcome after infant cardiac transplantation. J Heart Lung Transplant 23 (2004) 857-864
118. Qvist E., Jalanko H., and Holmberg C. Psychosocial adaptation after solid organ transplantation in children. Pediatr Clin North Am 50 (2003) 1505-1519
119. Serrano-Ikkos E., Lask B., Whitehead B., and Eisler I. Unsatisfactory adherence after pediatric heart and heart-lung transplantation. J Heart Lung Transplant 17 (1998) 1177-1183
120. Ringewald J., Gidding S., Crawford S., Backer C., Mavroudis C., and Pahl E. Nonadherence is associated with late rejection in pediatric heart transplant recipients. J Pediatr 139 (2001) 75-78
121. The US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. 2005 OPTN/SRTR annual report. http://www.ustransplant.org/annual_reports/current/ (accessed June 14, 2006)
122. Sweet S. Pediatric lung transplantation: update 2003. Pediatr Clin North Am 50 (2003) 1393-1417
123. Aris R., Routh J., LiPuma J., Heath D., and Gilligan P. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex; survival linked to genomovar type. Am J Respir Crit Care Med 164 (2001) 2102-2106
124. Chaparro C., Maurer J., Gutierrez C., et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med 163 (2001) 43-48
125. Huddleston C. Donor evaluation, surgical technique and perioperative management. In: Fine R., Webber S., Harmon W., Olthoff K., and Kelly D. (Eds). Pediatric solid organ transplantation. 2nd edn. (2006), Blackwell, London
126. Choong C., Sweet S., Zoole J., et al. Bronchial airway anastomotic complications after pediatric lung transplantation: incidence, cause, management, and outcome. J Thorac Cardiovasc Surg 131 (2006) 198-203
127. Meyers B., de la Morena M., Sweet S., et al. Primary graft dysfunction and other selected complications of lung transplantation: a single-center experience of 983 patients. J Thorac Cardiovasc Surg 129 (2005) 1421-1429
128. Aigner C., Winkler G., Jaksch P., et al. Size-reduced lung transplantation: an advanced operative strategy to alleviate donor organ shortage. Transplant Proc 36 (2004) 2801-2805
129. Starnes V., Bowdish M., Woo M., et al. A decade of living lobar lung transplantation: recipient outcomes. J Thorac Cardiovasc Surg 127 (2004) 114-122
130. Date H., Aoe M., Sano Y., et al. Improved survival after living-donor lobar lung transplantation. J Thorac Cardiovasc Surg 128 (2004) 933-940
131. Bowdish M., Barr M., Schenkel F., et al. A decade of living lobar lung transplantation: perioperative complications after 253 donor lobectomies. Am J Transplant 4 (2004) 1283-1288
132. Wagner K., Webber S., Kurland G., et al. New-onset diabetes mellitus in pediatric thoracic organ recipients under tacrolimus-based immunosuppression. J Heart Lung Transplant 16 (1997) 275-282
133. Hmiel S., Beck A., de la Morena M., and Sweet S. Progressive chronic kidney disease after pediatric lung transplantation. Am J Transplant 5 (2005) 1739-1747
134. Yousem S., Berry G., Cagle P., et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 15 (1996) 1-15
135. Choong C., Haddad F., Huddleston C., et al. Role of open lung biopsy in lung transplant recipients in a single children's hospital: a 13-year experience. J Thorac Cardiovasc Surg 131 (2006) 204-208
136. Danziger-Isakov L., Sweet S., Delamorena M., Huddleston C., Mendeloff E., and Debaun M. Epidemiology of bloodstream infections in the first year after pediatric lung transplantation. Pediatr Infect Dis J 24 (2005) 324-330
137. Danziger-Isakov L., Faro A., Sweet S., et al. Variability in standard care for cytomegalovirus prevention and detection in pediatric lung transplantation: survey of eight pediatric lung transplant programs. Pediatr Transplant 7 (2003) 469-473
138. Danziger-Isakov L., DeLaMorena M., Hayashi R., et al. Cytomegalovirus viremia associated with death or retransplantation in pediatric lung-transplant recipients. Transplantation 75 (2003) 1538-1543
139. Bridges N., Spray T., Collins M., Bowles N., and Towbin J. Adenovirus infection in the lung results in graft failure after lung transplantation. J Thorac Cardiovasc Surg 116 (1998) 617-623
140. Neuringer I., Chalermskulrat W., and Aris R. Obliterative bronchiolitis or chronic lung allograft rejection: a basic science review. J Heart Lung Transplant 24 (2005) 3-19
141. Sharples L., McNeil K., Stewart S., and Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant 21 (2002) 271-281
142. Davis Jr. R., Lau C., Eubanks S., et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg 125 (2003) 533-542
143. Benden C., Aurora P., Curry J., Whitmore P., Priestley L., and Elliott M. High prevalence of gastroesophageal reflux in children after lung transplantation. Pediatr Pulmonol 40 (2005) 68-71
144. Cooper J., Billingham M., Egan T., et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant 12 (1993) 713-716
145. Sritippayawan S., Keens T., Horn M., Starnes V., and Woo M. What are the best pulmonary function test parameters for early detection of post-lung transplant bronchiolitis obliterans syndrome in children?. Pediatr Transplant 7 (2003) 200-203
146. Brosig C. Psychological functioning of pediatric lung transplant candidates/recipients: a review of the literature. Pediatr Transplant 7 (2003) 390-394
147. Pearl J., Preston E., and Kirk A. Tolerance: is it achievable in pediatric solid organ transplantation?. Pediatr Clin North Am 50 (2003) 1261-1281
148. Guenther D., and Madsen J. Advances in strategies for inducing central tolerance in organ allograft recipients. Pediatr Transplant 9 (2005) 277-281